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Endometrial Polyps 
Background 
1. Localized outgrowth of endometrial glands and stroma that projects into the 
endometrial cavity  
o Most arise from fundus 
o Polypoid hyperplasia:  
 Multiple small polyps found throughout endometrial cavity 
o Rarely contain foci of neoplastic growth 
 
Pathophysiology 
1. Pathology of disease  
o Several proposed mechanisms of development  
 Monoclonal endometrial hyperplasia 
 Overexpression of endometrial aromatase 
 Gene mutations 
o 2/3 of polyps have immature endometrial tissue that does not respond to 
hormonal changes (non-functional polyps) 
o 1/3 have normal endometrium that changes with cyclic hormonal 
fluctuations (functional polyps)  
 Secretory or proliferative depending on the phase of the remaining 
endometrium 
o Malignant transformation  
 Estimated at up to 0.5% 
o Size  
 Range from millimeters to several centimeters  
2. Incidence, prevalence  
o Increasing identification  
 Due to widespread use of transvaginal ultrasonography and 
sonohysterography 
o 20-25% of reproductive-aged women  
 Peak incidence 40-49 yo 
o 10% incidence in autopsy studies 
o 23.8% incidence in symptomatic patients 
o 10-24% prevalence in women undergoing endometrial biopsy or 
hysterectomy 
3. Risk Factors  
o Increasing age 
o HTN 
o Menopausal status 
o Tamoxifen use  
 20-35% incidence of polyps in women on long-term tamoxifen 
4. Morbidity/ Mortality  
o Abnormal uterine bleeding  
 Metrorrhagia most common 
 Intermenstrual bleeding and menorrhagia also often seen 
 Polyps cause 25% of all abnormal vaginal bleeding 
o Extrusion from cervical os  
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 Causing pain 
 Spotting with intercourse 
o Malignant transformation 
o Endometrial hyperplasia 
o Infertility 
o Recurrent miscarriage 
 
Diagnostics 
1. History  
o Most are asymptomatic 
o Abnormal vaginal bleeding 
o Found incidentally  
 Vaginal ultrasound performed for other reasons 
2. Physical exam  
o May see tip of polyp extruding from cervical os 
o Most pts have normal exam 
3. Diagnostic testing  
o Laboratory evaluation  
 Negative evaluation for other causes of abnormal vaginal bleeding 
 Microscopic examination of tissue obtained from biopsy can 
distinguish between benign and malignant polyp 
o Diagnostic imaging  
 Transvaginal ultrasound may be negative 
 Sonohysterography is gold standard  
 US w/infusion of sterile saline into endometrial cavity to 
delineate structures 
 More accurate than transvaginal ultrasound in determining if 
polyps present 
 Most useful, non -invasive and cost -effective 
 Doppler flow studies do not appear to help distinguish between 
benign and malignant polyps 
 Combining ultrasound and sonohysterography does not significantly 
improve dx accuracy 
o Other studies  
 Hysteroscopy  
 Useful for diagnosis and resection 
 Resection and microscopic exam  
o Only reliable method to distinguish b/t benign and 
malignant polyps 
 Cervical cytology is not useful 
 
Differential Diagnosis 
1. Abnormal vaginal bleeding  
o Dysfunctional uterine bleeding 
o Uterine leiomyomata 
o Uterine adenomyosis 
o Endocrine abnormality (thyroid disease) 
o Endometrial hyperplasia or carcinoma 
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2. Direct visualization  
o Polypoid endometrial adenocarcinoma 
o Malignant polyp 
o Hyperplastic polyp 
o Leiomyoma 
o Adenomyosis 
 
Therapeutics 
1. Acute treatment  
o Surgical removal with hysterographic visualization is the mainstay of 
therapy 
o Improvement of symptoms in 75-100% of pts 
2. Recommendations  
o No data from randomized trials to guide therapy of asymptomatic polyps 
o Removal of symptomatic polyps (bleeding, infertility) [Grade 1C]
9
  
o Removal of asymptomatic polyps of any size in women with risk factors for 
endometrial hyperplasia / cancer [Grade 2C]
9
  
o Removal of asymptomatic polyps in women without risk factors if there are 
multiple polyps or  
 In premenopausal women, a single polyp exceeds 2 cm 
 In postmenopausal women, a single polyp exceeds 1 cm [Grade 2C]
9
  
o Expectant management of asymptomatic polyps 2 cm or less in 
premenopausal women or 1 cm or less in postmenopausal women without 
risk factors for endometrial hyperplasia / cancer since these polyps are more 
likely to regress [Grade 2C]
9
  
3. Surgical removal, w/hysterographic visualization  
o Mainstay of therapy 
 
Prognosis 
1. Increased risk of developing endometrial cancer in the future 
2. May cause infertility 
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